NYSE:NVS

Novartis Inaugurates Innovative Watershed Project in India to Increase Water Availability

Article

Today, on World Water Day, Novartis inaugurated an integrated watershed development project to help address water scarcity in the Telangana region of India, one of the world’s most water-stressed countries.

Novartis and the Bill & Melinda Gates Foundation Collaborate to Discover and Develop an Accessible in Vivo Gene Therapy for Sickle Cell Disease

Summary: 
  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
     
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Press Release
  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
     
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa

Novartis in Society US Report 2020

Reimagining healthcare in challenging times: Novartis in Society US
Article

Novartis is building a leading focused medicines company powered by advanced therapy platforms and data science. At the same time, we are pursuing innovative approaches to making pharmaceuticals more affordable and accessible and strengthening our communities and society. Since 2016, we have published an annual Novartis in Society US Report, which details our goals and activities in support of patients and their families, healthcare providers, the communities where we live and work, and our healthcare system.

Novartis Renews WHO Medicine Donation Pledge With Aim of Ending Leprosy

Summary: 
  • Novartis leprosy medicine donation program with WHO extended to 2025
  • Program has already treated over 7 million patients since 2000
  • New evidence from contact tracing and preventive treatment program shows route to accelerate elimination

Watch the Novartis Leprosy Youtube Video.

Access the Leprosy content on novartis.com.

Visit Novartis Global Health on Twitter and Linkedin.

Press Release
  • Novartis leprosy medicine donation program with WHO extended to 2025
  • Program has already treated over 7 million patients since 2000
  • New evidence from contact tracing and preventive treatment program shows route to accelerate elimination

Watch the Novartis Leprosy Youtube Video.

Access the Leprosy content on novartis.com.

Visit Novartis Global Health on Twitter and Linkedin.

Novartis and GSK Announce Collaboration to Support Scientific Research Into Genetic Diversity in Africa

Summary: 
  • Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients
  • Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years

  • Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by  March 1, 2021

Press Release
  • Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients
  • Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years

  • Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by  March 1, 2021

Novartis Set to Achieve 100% Renewable Electricity in Its European Operations

Press Release
  • Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical grid
  • Projects expected to address Novartis greenhouse gas emissions across its European operations, equivalent to removing approximately 113 000 passenger vehicles from the road annually1
  • Agreements mark a major milestone on the Novartis environmental sustainability journey to be carbon neutral across its operations by 2025 and across its supply chain by 2030

Contact Tracing With Prophylactic Treatment Could Near-Eliminate Leprosy in a Single Generation, New Research Suggests

Summary: 
  • Results from the Novartis Foundation-initiated Leprosy Post-Exposure Prophylaxis (LPEP) program covered more than 150,000 people across seven countries
  • Post-exposure prophylaxis with a single dose of the antibiotic rifampicin is safe, can be integrated into different leprosy control programs, and is generally well accepted by patients, their contacts, and health-care workers
  • Novartis has been committed to eliminating leprosy for over 30 years, with its multidrug therapy for the disease donated for free to over 7m patients since 2000
Press Release
  • Results from the Novartis Foundation-initiated Leprosy Post-Exposure Prophylaxis (LPEP) program covered more than 150,000 people across seven countries
  • Post-exposure prophylaxis with a single dose of the antibiotic rifampicin is safe, can be integrated into different leprosy control programs, and is generally well accepted by patients, their contacts, and health-care workers
  • Novartis has been committed to eliminating leprosy for over 30 years, with its multidrug therapy for the disease donated for free to over 7m patients since 2000

OLON Continues Strategic Collaboration With Novartis, Supporting the Expansion of the Africa Sickle Cell Disease Program to Kenya, Uganda and Tanzania

Press Release

October 1, 2020 /3BL Media/ - OLON announced it will continue its collaboration with Novartis to support the Africa Sickle Cell Disease program as it expands to Kenya, Uganda and Tanzania.  Initially launched in 2019 by Novartis and its partners in Ghana, the Africa Sickle Cell Disease program intends to improve the lives of people with sickle cell disease and accelerate access to treatment and related laboratory tests.

Life Science Companies and the Bill & Melinda Gates Foundation: Commitments to Expanded Global Access for COVID-19 Diagnostics, Therapeutics, and Vaccines

Press Release

September 30, 2020 /3BL Media/ - COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with civil society. As organizations dedicated to improving and protecting global health, with our varied skills, roles, and resources, we remain committed to doing our part in ending this pandemic worldwide.

Novartis US Foundation Commits $25M to Improve Health Equity by Reducing Health Disparities in the US

Summary: 
  • Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice
  • Commitment to include partnerships and support to address the underrepresentation of minorities, including African American/Black and Hispanic communities, in clinical trials
  • Reinforces US Foundation focus on improving health by strengthening health systems, eliminating barriers to care and addressing social determinants of health
Press Release
  • Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice
  • Commitment to include partnerships and support to address the underrepresentation of minorities, including African American/Black and Hispanic communities, in clinical trials
  • Reinforces US Foundation focus on improving health by strengthening health systems, eliminating barriers to care and addressing social determinants of health

Pages

Subscribe to NYSE:NVS